Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

(2020) Rajen Mody et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

(2019) Julie R. Park et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

(2018) Navin Pinto et al.   PEDIATRIC BLOOD & CANCER

Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma

(2018) Judith G. Villablanca et al.   PEDIATRIC BLOOD & CANCER

A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma

(2018) Theodoros N. Teknos et al.   INVESTIGATIONAL NEW DRUGS

Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients

(2017) K.C.J.M. Kraal et al.   EUROPEAN JOURNAL OF CANCER

Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131 I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma

(2017) Kevin Campbell et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

(2017) Rajen Mody et al.   LANCET ONCOLOGY

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

(2017) Evanthia Galanis et al.   NEURO-ONCOLOGY

Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer

(2016) Emily Chan et al.   RADIOTHERAPY AND ONCOLOGY

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma

(2016) Michiel Kroesen et al.   OncoImmunology

Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma

(2015) S G DuBois et al.   BRITISH JOURNAL OF CANCER

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

(2015) S. G. DuBois et al.   CLINICAL CANCER RESEARCH

Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial

(2014) Wenyin Shi et al.   JOURNAL OF NEURO-ONCOLOGY

A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma

(2013) Jayne S. Wilson et al.   EUROPEAN JOURNAL OF CANCER

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

(2012) S. G. DuBois et al.   CLINICAL CANCER RESEARCH

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms

(2011) Sabine Mueller et al.   CANCER LETTERS

Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma In Vitro and In Vivo Model Systems

(2011) S. S. More et al.   CLINICAL CANCER RESEARCH

Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic

(2011) Jacob E. Shabason et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

(2011) Wendy B. London et al.   JOURNAL OF CLINICAL ONCOLOGY

Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report

(2010) Maryam Fouladi et al.   JOURNAL OF CLINICAL ONCOLOGY

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

(2010) Anne Hansen Ree et al.   LANCET ONCOLOGY

Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination

(2008) A G McCluskey et al.   BRITISH JOURNAL OF RADIOLOGY